
Rentomojo targets IPO by FY27 as revenues, profits grow
BENGALURU
:
Rentomojo, a Bengaluru-based furniture and appliance rental startup, is preparing for a public listing in the next 18 to 24 months, making it the first company in its sector to aim for an IPO in India, according to its investors.
As part of the pre-IPO push, the company is also looking to raise a fresh funding round and onboard independent directors. 'My job is moving from that of a CEO towards being a promoter or imagining myself as a promoter of a listed entity," said Geetansh Bamania, founder of Rentomojo.
The startup last raised ₹210 crore in February 2024 in its Series D and D1 round, which was led by Edelweiss Discovery Fund Series — I and included participation from Chiratae Ventures and Magnetic Ventures. Other investors include Accel and Bain Capital.
Also Read: Swiggy delivers for Prosus with 23% IRR, venture portfolio a mixed bag
For FY25, Rentomojo reported unaudited net revenue of ₹270 crore and Ebitda of ₹95 crore—up 44% from ₹66 crore the previous year. Net profit rose to ₹40 crore from ₹22 crore in FY24, marking an 82% jump. The company claims a return on capital employed of over 20%, with potential subscription revenue of ₹650 crore as of 31 March 2025. Rentomojo's first profitable year was in FY23, when it posted ₹6.2 crore in profit, alongside operating revenue of ₹121 crore in that fiscal.
In comparison, the company's closest rival, Furlenco, saw its operating revenue in FY24 decline 10.4% to ₹139.6 crore, down from ₹155.8 crore in FY23. According to Entrackr, its losses also widened from ₹128 crore in FY23 to ₹130 crore.
'It's more of a milestone. It's not the end but the beginning of a new journey altogether. I'll be selling a smaller portion, if at all," Bamania said of the IPO.
Furniture and appliances each contribute 50% of Rentomojo's revenue. Bamania noted a surge in demand for water purifiers—a key product for consumers in transferable jobs in the service industry, particularly those in mid- to lower-level management roles
Also Read: Nurix AI targets $10 million in annual revenue in voice-first agentic AI push
Water purifiers are quickly becoming a hotly contested segment as legacy players like Aquaguard, Kent RO face increasing competition from newer entrants like Urban Company's Native brand. Others, like Livpure offer customers a subscription plan to water purifiers whereas appliance maker Atomberg has recently launched a water purifiers.
Quality through stores
An interesting revenue stream is refurbished furniture, which made up 10% of FY25's revenue. 'This was the biggest taboo in our rental industry that if the sofa comes to you, what shape or form it will be received in," Bamania said. 'To combat that, opening retail stores was one of the biggest objectives for us."
To address quality concerns, the company invested in a 'phygital" retail strategy, launching physical stores across India. It currently operates over 50 outlets, including 27 to 29 in Bengaluru, six in NCR, and others in Pune, Hyderabad, and Chandigarh. A 51st store will open in Mumbai.
'We took a step to open the retail stores with a lot of assumptions, and those objectives worked out for us," Bamania said.
Rentomojo's offline push is aligned with a broader trend among D2C startups in India. Despite the growth of online retail, nearly 90% of India's projected $2 trillion retail market in 2030 will still be offline, according to a Redseer, Accel, and Fireside Ventures report. The same study found that omnichannel shoppers spend 2.5 times more than single-channel consumers.
Also Read: Japan's BeyondNext Ventures sets sights on Indian startups with $50 million fund
Rentomojo was started in 2014 by Bamania and Ajay Nainto to serve a new generation of urban Indian professionals who move cities frequently for work. The startup's subscription model allows customers to rent household essentials without committing to ownership—an offering increasingly relevant in India's gig and service economy.
As it moves closer to an IPO, the company is increasing its focus on operational efficiency, customer trust, and scalable growth—all essential ingredients as it transitions from startup to listed entity.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
18 minutes ago
- New Indian Express
Ample Parks launches industrial and logistics park at Mahindra World City
CHENNAI: Ample Parks, a joint venture between UK-based private equity firm Actis and Mahindra Lifespaces, has launched a 71-acre industrial and logistics park within the Domestic Tariff Area (DTA) of Mahindra World City (MWC), marking its foray into industrial real estate market. Backed by a planned investment of Rs 800 crore, the facility is the largest Grade-A industrial space within MWC's DTA and one of the few large-format developments of its kind in the region. The company plans to expand its land portfolio tenfold over the next five to seven years to build a pan-India platform. Located along the Oragadam-Maraimalai Nagar corridor, the park is designed to cater to industries including automotive, engineering, electronics and white goods. It offers 2.1 million sq ft of leasable area with both ready-to-move-in and built-to-suit options. Once fully operational, the park is expected to generate Rs 110 crore in annual revenue and over Rs 1,400 crore in a decade. It is also projected to create nearly 11,000 direct and indirect jobs. 'Ample Parks MWC is a future-ready ecosystem that integrates industrial, commercial, and logistics capabilities,' said Akash Rastogi, CEO and Director of Ample Parks. 'This is just the beginning, we intend to replicate this model across India's high-growth corridors.'


Time of India
33 minutes ago
- Time of India
Global goods trade gains as tariff fears speed imports, WTO says
Tired of too many ads? Remove Ads Global merchandise trade accelerated in the World Trade Organization's latest assessment, with a surge in imports tied to tariff stockpiling outweighing a slowdown in export WTO 's goods barometer rose to 103.5 in the first quarter, the highest level since August 2021, from the previous reading of 102.8, released in March, the Geneva-based organization said Thursday. The baseline of 100 indicates growth over the next quarter that's in line with medium-term orders were the only category in negative territory, the data showed. Increases were seen in air freight and container shipping along with rising demand for autos and electronics, the WTO President Donald Trump's higher taxes on goods entering the US — and threats to raise them even higher — have led companies to rush orders to avoid the extra costs.'This indicates strong trade volume growth in the first several months of 2025 possibly due to importers moving up purchases of goods in anticipation of higher tariffs in the future,' the report said. 'If so, trade growth should slow later in the year as sellers draw down inventories rather than importing more goods.'
&w=3840&q=100)

Business Standard
41 minutes ago
- Business Standard
Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious
Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. Tanmay Tiwary New Delhi Torrent Pharma share price today: Pharmaceutical company Torrent Pharmaceuticals shares were in focus on Monday, June 30, after the company announced a massive ₹25,689-crore deal to acquire JB Chemicals & Pharmaceuticals (JBCP). The Torrent Pharmaceuticals share surged as much as 3.89 per cent intraday to ₹3,474.60 apiece before paring gains. At last count, shares were trading 0.72 per cent higher at ₹3,368.35, even as the BSE Sensex remained flat around 84,003.81. The deal Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. The transaction, structured in two phases, begins with Torrent Pharmaceuticals acquiring 46.39 per cent stake via a share purchase agreement (SPA) at ₹1,600 per share, amounting to ₹11,917 crore. This will be followed by an open offer to buy up to 26 per cent from public shareholders at ₹1,639 per share. Additionally, Torrent Pharmaceuticals said that it aims to acquire 2.8 per cent of JB Chemicals and Pharmaceuticals' equity from certain employees at the same price offered to KKR. As part of the transaction, Torrent Pharmaceuticals and JB Chemicals and Pharmaceuticals will merge—JB Chemicals shareholders will receive 51 Torrent Pharmaceuticals' shares for every 100 JB Chemicals and Pharmaceuticals shares held. The deal is now pending shareholder and Competition COmmission of India (CCI) approvals and is expected to close in six months. Brokerages' view Brokerages broadly see the deal as strategically major, though the near-term impact remains mixed. According to domestic brokerage firm Motilal Oswal, the acquisition provides Torrent Pharmaceuticals with a diversified branded portfolio that includes several potential mega brands, a pan-India reach supported by a 2,800-strong medical representative field force, robust manufacturing infrastructure for multiple dosage forms, and access to a growing Contract Development and Manufacturing Organisation (CDMO) business driven by lozenges. The brokerage believes this acquisition is value accretive over the medium to long-term. Excluding the impact of JB Chemicals and Pharmaceuticals, Torrent Pharmaceuticals is expected to post a 12 per cent revenue, 14 per cent Ebitda, and 23 per cent PAT CAGR over FY25–27. The brokerage values the stock at 38x 12-month forward earnings, arriving at a target price of ₹3,430. However, it maintained a 'Neutral' rating, citing limited upside from current levels despite the deal's long-term merits. Those at Japan-based foreign brokerage firm Nomura noted that the move aligns with Torrent Pharmaceuticals' history of inorganic growth, particularly in India. The acquisition offers near-term cost synergies and potential long-term revenue synergies, especially as both firms have a dominant presence in the Cardiac and Gastro segments. However, it flagged concerns around execution risks given the unprecedented size of this deal for Torrent. Unlike past acquisitions, valuation premiums are higher, and there's limited headroom for operational improvement as JBCP is already a well-run business with strong market share in key products. In the near-term, the acquisition could be earnings dilutive, especially when factoring in higher interest and amortisation costs. Excluding amortisation, the deal may be marginally EPS accretive—if merged using Torrent stock. Thus, Nomura maintained a 'Neutral' rating on Torrent Pharmaceuticals with a target price of ₹3,580, based on 25x FY27 Ebitda of ₹4,850 crore. The stock currently trades at 26.1x one-year forward Ebitda. While analysts are mixed on the immediate financial impact, the Street appears optimistic about Torrent Pharmaceuticals' long-term strategic play in scaling up its domestic and international presence through this acquisition.